Respiratory syncytial virus (RSV) causes acute exacerbations in COPD and asthma. RSV infects bronchial epithelial cells (HBE) that trigger RSV associated lung pathology. This study explores whether the phosphodiesterase 4 (PDE4) inhibitor Roflumilast N-oxide (RNO), alters RSV infection of well-differentiated HBE (WD-HBE) in vitro. WD-HBE were RSV infected in the presence or absence of RNO (0.1-100 nM). Viral infection (staining of F and G proteins, nucleoprotein RNA level), mRNA of ICAM-1, ciliated cell markers (digital high speed videomicroscopy, β-tubulin immunofluorescence, Foxj1 and Dnai2 mRNA), Goblet cells (PAS), mRNA of MUC5AC and CLCA1, mRNA and protein level of IL-13, IL-6, IL-8, TNFα, formation of H2O2 and the anti-oxidative armamentarium (mRNA of Nrf2, HO-1, GPx; total antioxidant capacity (TAC) were measured at day 10 or 15 post infection. RNO inhibited RSV infection of WD-HBE, prevented the loss of ciliated cells and markers, reduced the increase of MUC5AC and CLCA1 and inhibited the increase of IL-13, IL-6, IL-8, TNFα and ICAM-1. Additionally RNO reversed the reduction of Nrf2, HO-1 and GPx mRNA levels and consequently restored the TAC and reduced the H2O2 formation. RNO inhibits RSV infection of WD-HBE cultures and mitigates the cytopathological changes associated to this virus.
References
[1]
Nair H, Nokes DJ, Gessner BD, Dherani M, Madhi SA et al. (2010) Global burden of acute lower respiratory infections due to respiratory syncytial virus in young children: a systematic review and meta-analysis. Lancet 375(9725): 1545-1555. doi:10.1016/S0140-6736(10)60206-1. PubMed: 20399493.
[2]
Falsey AR, Walsh EE (2005) Respiratory syncytial virus infection in elderly adults. Drugs Aging 22(7):577-87.
[3]
Hansbro NG, Horvat JC, Wark PA, Hansbro PM (2008) Understanding the mechanisms of viral induced asthma: new therapeutic directions. Pharmacol Ther 117: 313-353. doi:10.1016/j.pharmthera.2007.11.002. PubMed: 18234348.
[4]
Ramaswamy M, Groskreutz DJ, Look DC (2009) Recognizing the importance of respiratory syncytial virus in chronic obstructive pulmonary disease. COPD 6: 64-75. doi:10.1080/15412550902724024. PubMed: 19229710.
[5]
Mukherjee S, Lukacs NW (2010) Association of IL-13 in respiratory syncytial virus-induced pulmonary disease: still a promising target. Expert Rev Anti Infect Ther 8: 617-621. doi:10.1586/eri.10.39. PubMed: 20521887.
[6]
Okada SF, Zhang L, Kreda SM, Abdullah LH, Davis CW et al. (2011) Coupled nucleotide and mucin hypersecretion from goblet-cell metaplastic human airway epithelium. Am J Respir Cell Mol Biol 45: 253-260. doi:10.1165/rcmb.2010-0253OC. PubMed: 20935191.
[7]
Mata M, Morcillo E, Gimeno C, Cortijo J (2011) N-acetyl-L-cysteine (NAC) inhibit mucin synthesis and pro-inflammatory mediators in alveolar type II epithelial cells infected with influenza virus A and B and with respiratory syncytial virus (RSV). Biochem Pharmacol 82: 548-555. doi:10.1016/j.bcp.2011.05.014. PubMed: 21635874.
[8]
Villenave R, Thavagnanam S, Sarlang S, Parker J, Douglas I et al. (2012) In vitro modeling of respiratory syncytial virus infection of pediatric bronchial epithelium, the primary target of infection in vivo. Proc Natl Acad Sci USA 109: 5040-5045. doi:10.1073/pnas.1110203109. PubMed: 22411804.
[9]
Mata M, Sarrion I, Armengot M, Carda C, Martinez I et al. (2012) Respiratory syncytial virus inhibits ciliagenesis in differentiated normal human bronchial epithelial cells: effectiveness of N-acetylcysteine. PLOS ONE 7: e48037. doi:10.1371/journal.pone.0048037. PubMed: 23118923.
[10]
Lay MK, González PA, León MA, Céspedes PF, Bueno SM et al. (2013) Advances in understanding respiratory syncytial virus infection in airway epithelial cells and consequential effects on the immune response. Microbes Infect, Dec (e-pub ahead of print) . PubMed : 23246463.
[11]
Garofalo RP, Kolli D, Casola A (2013) Respiratory syncytial virus infection: mechanisms of redox control and novel therapeutic opportunities. Antoxid Redox Signal 18: 186-217.
[12]
Conti M, Beavo J (2007) Biochemistry and physiology of cyclic nucleotide phosphodiesterases: essential components in cyclic nucleotide signaling. Annu Rev Biochem 76: 481-511. doi:10.1146/annurev.biochem.76.060305.150444. PubMed: 17376027.
[13]
Francis SH, Houslay MD, Conti M (2011) Phosphodiesterase inhibitors: factors that influence potency, selectivity, and action. Handb Exp Pharmacol 204: 47-84. doi:10.1007/978-3-642-17969-3_2. PubMed: 21695635.
[14]
Schudt C, Hatzelmann A, Beume R, Tenor H (2011) Phosphodiesterase inhibitors: history of pharmacology. Handb Exp Pharmacol 204: 1-46. doi:10.1007/978-3-642-17969-3_1. PubMed: 21695634.
[15]
Wright LC, Seybold J, Robichaud A, Adcock IM, Barnes PJ (1998) Phosphodiesterase expression in human epithelial cells. Am J Physiol 275: L694-L700. PubMed: 9755101.
[16]
Dent G, White SR, Tenor H, Bodtke K, Schudt C et al. (1998) Cyclic nucleotide phosphodiesterase in human bronchial epithelial cells: characterization of isoenzymes and functional effects of PDE inhibitors. Pulm Pharmacol Ther 11: 47-56. doi:10.1006/pupt.1998.0115. PubMed: 9802963.
[17]
Fuhrmann M, Jahn HU, Seybold J, Neurohr C, Barnes PJ et al. (1999) Identification and function of cyclic nucleotide phosphodiesterase isoenzymes in airway epithelial cells. Am J Respir Cell Mol Biol 20: 292-302. doi:10.1165/ajrcmb.20.2.3140. PubMed: 9922221.
[18]
Mata M, Sarriá B, Buenestado A, Cortijo J, Cerdá M et al. (2005) Phosphodiesterase 4 inhibition decreases MUC5AC expression induced by epidermal growth factor in human airway epithelial cells. Thorax 60: 144-152. doi:10.1136/thx.2004.025692. PubMed: 15681504.
[19]
Barnes AP, Livera G, Huang P, Sun C, O’Neal WK et al. (2005) Phosphodiesterase 4D forms a cAMP diffusion barrier at the apical membrane of the airway epithelium. J Biol Chem 280: 7997-8003. PubMed: 15611099.
[20]
Kolosionek E, Savai R, Ghofrani HA, Weissmann N, Guenther A et al. (2009) Expression and activity of phosphodiesterase isoforms during epithelial mesenchymal transition: the role of phosphodiesterase 4. Mol Biol Cell 20: 4751-4765. doi:10.1091/mbc.E09-01-0019. PubMed: 19759179.
[21]
Milara J, Armengot M, Ba?uls P, Tenor H, Beume R et al. (2012) Roflumilast N-oxide, a PDE4 inhibitor, improves cilia motility and ciliated human bronchial epithelial cells compromised by cigarette smoke in vitro. Br J Pharmacol 166: 2243-2262. doi:10.1111/j.1476-5381.2012.01929.x. PubMed: 22385203.
[22]
Meja KK, Catley MC, Cambridge LM, Barnes PJ, Lum H et al. (2004) Adenovirus-mediated delivery and expression of a cAMP-dependent protein kinase inhibitor gene to BEAS-2B epithelial cells abolishes the anti-inflammatory effects of rolipram, salbutamol, and prostaglandin E2: a comparison with H-89. J Pharmacol Exp Ther 309: 833-844. doi:10.1124/jpet.103.060020. PubMed: 14747610.
[23]
Murphy DM, Ward C, Forrest IA, Pritchard G, Jones D et al. (2006) The phosphodiesterase type IV inhibitor cilomilast decreases pro-inflammatory cytokine production from primary bronchial epithelial cells in lung transplantation patients. J Heart Lung Transplant 25: 1436-1440. doi:10.1016/j.healun.2006.09.005. PubMed: 17178338.
[24]
Reddy PJ, Aksoy MO, Yang Y, Li XX, Ji R et al. (2008) Inhibition by salmeterol and cilomilast of fluticasone-enhanced IP-10 release in airway epithelial cells. COPD 5: 5-11. doi:10.1080/15412550701817573. PubMed: 18259970.
[25]
Pace E, Ferraro M, Uasuf CG, Giarratano A, La Grutta S et al. (2011) Cilomilast counteracts the effects of cigarette smoke in airway epithelial cells. Cell Immunol 268: 47-53. doi:10.1016/j.cellimm.2011.02.004. PubMed: 21382614.
[26]
Calverley PM, Rabe KF, Goehring UM, Kristiansen S, Fabbri LM et al. (2009) Roflumilast in symptomatic chronic obstructive pulmonary disease: two randomised clinical trials. Lancet 374: 685-694. doi:10.1016/S0140-6736(09)61255-1. PubMed: 19716960.
[27]
Fabbri LM, Calverley PM, Izquierdo-Alonso JL, Bundschuh DS, Brose M et al. (2009) Roflumilast in moderate-to-severe chronic obstructive pulmonary disease treated with longacting bronchodilators: Two randomised clinical trials. Lancet 374: 695-703. doi:10.1016/S0140-6736(09)61252-6. PubMed: 19716961.
[28]
Bateman ED, Rabe KF, Calverley PM, Goehring UM, Brose M et al. (2011) Roflumilast with long-acting β2-agonists for COPD: influence of exacerbation history. Eur Respir J 38: 553-560. doi:10.1183/09031936.00178710. PubMed: 21737553.
[29]
Rennard SI, Calverley PM, Goehring UM, Bredenbr?ker D, Martinez FJ (2011) Reduction of exacerbations by the PDE4 inhibitor roflumilast--the importance of defining different subsets of patients with COPD. Respir Res 12: 18. doi:10.1186/1465-9921-12-18. PubMed: 21272339.
[30]
Rabe KF (2011) Update on roflumilast, a phosphodiesterase 4 inhibitor for the treatment of chronic obstructive pulmonary disease. Br J Pharmacol 163: 53-67. doi:10.1111/j.1476-5381.2011.01218.x. PubMed: 21232047.
[31]
Gower TL, Graham BS (2001) Antiviral activity of lovastatin against respiratory syncytial virus in vivo and in vitro. Antimicrob Agents Chemother 45: 1231-1237. doi:10.1128/AAC.45.4.1231-1237.2001. PubMed: 11257039.
[32]
Asada M, Yoshida M, Hatachi Y, Sasaki T, Yasuda H et al. (2012) l-carbocisteine inhibits respiratory syncytial virus infection in human tracheal epithelial cells. Respir Physiol Neurobiol 180: 112-118. doi:10.1016/j.resp.2011.10.017. PubMed: 22080978.
[33]
Iesato K, Tatsumi K, Saito K, Ogasawara T, Sakao S et al. (2008) Tiotropium bromide attenuates respiratory syncytial virus replication in epithelial cells. Respiration 76: 434-441. doi:10.1159/000151729. PubMed: 18728351.
[34]
Asada M, Yoshida M, Suzuki T, Hatachi Y, Sasaki T et al. (2009) Macrolide antibiotics inhibit respiratory syncytial virus infection in human airway epithelial cells. Antiviral Res 83: 191-200. doi:10.1016/j.antiviral.2009.05.003. PubMed: 19463856.
[35]
Arnold R, K?nig W (2006) Peroxisome proliferator-activated receptor-gamma agonists inhibit the replication of respiratory syncytial virus (RSV) in human lung epithelial cells. Virology 350: 335-346. doi:10.1016/j.virol.2006.03.008. PubMed: 16616290.
[36]
Bethke TD, B?hmer GM, Hermann R, Hauns B, Fux R et al. (2007) Dose-proportional intraindividual single- and repeated-dose pharmacokinetics of roflumilast, an oral, once-daily phosphodiesterase 4 inhibitor. J Clin Pharmacol 47: 26-36. doi:10.1177/0091270006294529. PubMed: 17192499.
[37]
Hatzelmann A, Morcillo EJ, Lungarella G, Adnot S, Sanjar S et al. (2010) The preclinical pharmacology of roflumilast - a selective, oral phosphodiesterase 4 inhibitor in development for chronic obstructive pulmonary disease. Pulm Pharmacol Ther 23: 235-256. doi:10.1016/j.pupt.2010.03.011. PubMed: 20381629.
[38]
Martínez I, Dopazo J, Melero JA (1997) Antigenic structure of the human respiratory syncytial virus G glycoprotein and relevance of hypermutation events for the generation of antigenic variants. J Gen Virol 78 ( Pt 10): 2419-2429. . PubMed : 9349460.
[39]
Mbiguino A, Menezes J (1997) Purification of human respiratory syncytial virus: superiority of sucrose gradient over percoll, renografin, and metrizamide gradients. J Virol Methods 31: 161-170. PubMed: 1650782.
[40]
Armengot M, Milara J, Mata M, Carda C, Cortijo J (2010) Cilia motility and structure in primary and secondary ciliary dyskinesia. Am J Rhinol Allergy; 24: 175-180. doi:10.2500/ajra.2010.24.3448. PubMed: 20537282.
[41]
Look DC, Walter MJ, Williamson MR, Pang L, You Y et al. (2001) Effects of Paramyxoviral Infection on Airway Epithelial Cell Foxj1 Expression, Ciliogenesis, and Mucociliary Function. Am J Pathol 159: 2055-2069. doi:10.1016/S0002-9440(10)63057-X. PubMed: 11733356.
[42]
Bell EL, Klimova TA, Eisenbart J, Moraes CT, Murphy MP et al. (2007) The Qo site of the mitochondrial complex III is required for the transduction of hypoxic signaling via reactive oxygen species production. J Cell Biol 177: 1029-1036. doi:10.1083/jcb.200609074. PubMed: 17562787.
[43]
H?hne K, Schlie?mann SJ, Kirschbaum A, Pl?nes T, Müller-Quernheim J et al. (2012) Roflumilast-N-oxide induces surfactant protein expression in human alveolar epithelial cells type II. PLOS ONE 7(7): e38369. doi:10.1371/journal.pone.0038369. PubMed: 22815690.
[44]
Kwak HJ, Song JS, Heo JY, Yang SD, Nam JY et al. (2005) Roflumilast inhibits lipopolysaccharide-induced inflammatory mediators via suppression of nuclear factor-kappaB, p38 mitogen-activated protein kinase, and c-Jun NH2-terminal kinase activation. J Pharmacol Exp Ther 315(3): 1188-1195. doi:10.1124/jpet.105.092056. PubMed: 16126838.
[45]
Growcott EJ, Spink KG, Ren X, Afzal S, Banner KH et al. (2006) Phosphodiesterase type 4 expression and anti-proliferative effects in human pulmonary artery smooth muscle cells. Respir Res 7:9. PubMed: 16423283.
[46]
López-Campos JL, Gutiérrez C, Calero C (2012) The potential role of racecadotril in the treatment of diarrhea associated with roflumilast. Arch Bronconeumol 48(11): 426. doi:10.1016/j.arbres.2012.03.002. PubMed: 22560927.
[47]
Kwak HJ, Park KM, Choi HE, Chung KS, Lim HJ et al. (2008) PDE4 inhibitor, roflumilast protects cardiomyocytes against NO-induced apoptosis via activation of PKA and Epac dual pathways. Cell Signal 20(5): 803-814. doi:10.1016/j.cellsig.2007.12.011. PubMed: 18276108.
[48]
Mastrangelo P, Hegele RG (2012) The RSV fusion receptor: not what everyone expected it to be. Microbes Infect 14: 1205-1210. doi:10.1016/j.micinf.2012.07.015. PubMed: 22884716.
[49]
Leverence JT, Medhora M, Konduri GG, Sampath V (2011) Lipopolysaccharide-induced cytokine expression in alveolar epithelial cells: role of PKCζ-mediated p47phox phosphorylation. Chem Biol Interact 189(1–2): 72–81. PubMed: 20920494.
[50]
Fink K, Duval A, Martel A, Soucy-Faulkner A, Grandvaux N (2008) Dual role of NOX2 in respiratory syncytial virus- and sendai virus-induced activation of NF-kappaB in airway epithelial cells. J Immunol 180: 6911-6922. PubMed: 18453612.
[51]
Hosakote YM, Liu T, Castro SM, Garofalo RP, Casola A (2009) Respiratory syncytial virus induces oxidative stress by modulating antioxidant enzymes. Am J Respir Cell Mol Biol 41: 348-357. doi:10.1165/rcmb.2008-0330OC. PubMed: 19151318.
[52]
Hosakote YM, Jantzi PD, Esham DL, Spratt H, Kurosky A (2011) Viral-mediated inhibition of antioxidant enzymes contributes to the pathogenesis of severe respiratory syncytial virus bronchiolitis. Am J Respir Crit Care Med 183: 1550-1560. doi:10.1164/rccm.201010-1755OC. PubMed: 21471094.
[53]
Kokot A, Metze D, Mouchet N, Galibert MD, Schiller M (2009) Alpha-melanocyte-stimulating hormone counteracts the suppressive effect of UVB on Nrf2 and Nrf-dependent gene expression in human skin. Endocrinology 150: 3197-3206. doi:10.1210/en.2008-1315. PubMed: 19282378.
[54]
Cho HY, Imani F, Miller-DeGraff L, Walters D, Melendi GA et al. (2009) Antiviral activity of Nrf2 in a murine model of respiratory syncytial virus disease. Am J Respir Crit Care Med 179: 138-150. doi:10.1164/rccm.200804-535OC. PubMed: 18931336.
[55]
Dimopoulos G, Lerikou M, Tsiodras S, Perros E, Anagnostopoulou U et al. (2012) Viral epidemiology of acute exacerbations of chronic obstructive pulmonary disease. Pulm Pharmacol Ther 25: 12-18. doi:10.1016/j.pupt.2011.08.004. PubMed: 21983132.
[56]
Cortijo J, Iranzo A, Milara X, Mata M, Cerdá-Nicolás M et al. (2009) Roflumilast, a phosphodiesterase 4 inhibitor, alleviates bleomycin-induced lung injury. Br J Pharmacol 156(3): 534-544. doi:10.1111/j.1476-5381.2008.00041.x. PubMed: 19154443.